learn Hair Multiplication
extract, clone, and reinsert your own hair cells
Search
forProducts matching "pharmaceutical release"
Tracking 1 products like 165 Urimax D (Tamsulosin HCl/Dutasteride 0.4mg/0.5mg) from by companies like Inhouse Pharmacy. View product »Learn
5 / 7 resultslearn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn Mesotherapy
technique to inject very small amounts of beneficial chemicals into the scalp
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Dexpanthenol
precursor of vitamin B5 with hair stimulating effects
Research
5 / 1000+ results
research Mucoadhesive Polymer Hyaluronan as Biodegradable Cationic/Zwitterionic Drug Delivery Vehicle
Hyaluronan is a good drug delivery material because it sticks to mucosal areas and its drug release can be improved by changing its properties.
research Resveratrol Derivatives: A Patent Review (2009–2012)
New resveratrol-related compounds show promise for treating various health issues but need more research for clinical use.
research Development and Characterization of Thiolated Cyclodextrin-Based Nanoparticles for Topical Delivery of Minoxidil
The new adhesive nanoparticles are effective for delivering Minoxidil to the scalp without skin irritation.
research Environmental Endocrine Disrupting Chemicals and Their Epigenetic Influence on Androgenetic Alopecia
Environmental factors and chemicals might affect hormone balance and contribute to common hair loss.
research Physicochemical Properties of pH-Sensitive Hydrogels Based on Hydroxyethyl Cellulose–Hyaluronic Acid for Transdermal Delivery Systems for Skin Lesions
The hydrogel with a 1:3 ratio of hydroxyethyl cellulose to hyaluronic acid is effective for delivering drugs through the skin to treat acne.
Community Join
5 / 331 resultscommunity Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Massive study on finasteride side effects released
The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.